The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab

Conclusions
When followed prospectively, most patients who develop ATI do so within the first 12 months of therapy. This incidence is reduced by concomitant immunomodulator even in scheduled-therapy patients. In contrast, transient ATI, which are of little clinical significance, can appear haphazardly at any time during treatment. The onset of clinical loss of response may lag behind the appearance of anti-infliximab antibodies.

Source: Gut - July 8, 2014 Category: Gastroenterology Authors: Ungar, B., Chowers, Y., Yavzori, M., Picard, O., Fudim, E., Har-Noy, O., Kopylov, U., Eliakim, R., Ben-Horin, S., on behalf of ABIRISK consortium Tags: Crohn's disease, Ulcerative colitis Inflammatory bowel disease Source Type: research